Joining a Clinical Trial for Thyroid Cancer
If you or a loved one has thyroid cancer, you may have heard your care team mention a clinical trial (a research study that tests a new treatment, test, or way of managing a disease in people). For most people with the common forms of thyroid cancer, papillary and follicular carcinoma (together called differentiated thyroid cancer, or DTC), standard treatment works very well. But for people whose cancer no longer responds to standard treatment, and for people with medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC), a clinical trial can open the door to newer, more targeted options.
What Is a Clinical Trial?
A clinical trial is a carefully designed research study that tests whether a new drug, drug combination, device, or approach to care is safe and whether it works. Before any new cancer treatment can be offered widely, it must go through this kind of testing in real patients. Every clinical trial follows a written plan called a protocol, which spells out exactly who can join, what will be done, and how results will be measured. An independent review board also checks the plan to help protect the safety and rights of everyone who takes part.
Clinical trials matter for every type of cancer, but they matter in a very specific way for thyroid cancer. Most differentiated thyroid cancer is treated successfully with surgery and, when needed, radioactive iodine (RAI), so many patients never need a trial. But treatment options become more limited once a cancer stops responding to standard therapy, and they are especially limited for medullary thyroid cancer and anaplastic thyroid cancer. Trials are how new options for these harder-to-treat situations get discovered and proven.
Medullary thyroid cancer works differently from the more common types. It starts in C cells (calcitonin-producing cells) rather than the follicular cells that give rise to papillary and follicular thyroid cancer, so it is not treated with radioactive iodine. Research into the RET gene, which drives many cases of medullary thyroid cancer, led directly to targeted drugs being tested and later approved in clinical trials, giving patients options that did not exist a decade ago.
Anaplastic thyroid cancer is rare, grows quickly, and is treated as a medical emergency requiring urgent, coordinated care from a multidisciplinary team. It has a much more difficult prognosis than differentiated or medullary thyroid cancer. Clinical trials have driven some of the most meaningful recent progress here, particularly for tumors with a BRAF V600E mutation (a specific genetic change in the tumor that can be targeted with certain drugs), where a combination of targeted therapy drugs has shown real, measurable benefit in trial participants.
Joining a clinical trial also contributes to something bigger than any one person's treatment. Every approved thyroid cancer drug available today, including the targeted therapies now used for RET-altered medullary thyroid cancer and BRAF mutant anaplastic thyroid cancer, reached patients because earlier volunteers took part in a trial. You can read more about thyroid cancer treatment options generally, and how they differ by subtype, in our companion guide.
Not everyone who joins a clinical trial is trying an experimental treatment as a last resort. Some trials test new combinations of already approved drugs, better ways to reduce side effects, or improved supportive care. Understanding this range can help you see a trial as one more tool your care team may offer, not just an emergency measure.
What Are the Phases of a Clinical Trial?
Cancer treatment trials move through a series of steps called phases, and each phase answers a different question. According to the National Cancer Institute (NCI), a treatment usually must show good results in one phase before it can move on to the next.
Phase 1 trials are the first time a new treatment is tested in people. It usually involves a small group, around 15 to 30 people, and its main goal is safety: figuring out side effects, the highest dose people can tolerate, and whether the treatment has any effect on the cancer at all.
Phase 2 trials include more participants, usually 50 to 100 people, and look more closely at whether the treatment actually works against the cancer, such as by shrinking tumors or slowing their growth. Researchers continue to watch closely for short-term side effects during this phase.
Phase 3 trials compare the new treatment directly against the current standard treatment, often in hundreds to several thousand people. Participants are usually assigned by chance (called randomization) to one treatment group or the other, which helps researchers trust that any difference in results is real and not due to who happened to get which treatment. Results from Phase 1 through Phase 3 trials are what the US Food and Drug Administration (FDA) uses to decide whether to approve a new treatment.
Phase 4 trials happen after a treatment is already approved and available to the public. These trials continue to track long-term safety and effectiveness in large, varied groups of people over time, since some rare side effects only become clear once a drug is used more widely. Placebos (inactive treatments used for comparison) are rarely used in cancer treatment trials, and if one is part of a trial, you will always be told in advance.
Should You Join a Clinical Trial for Thyroid Cancer?
Whether a clinical trial makes sense for you depends heavily on your specific diagnosis. People with differentiated thyroid cancer that has stopped responding to radioactive iodine, often called RAI-refractory disease, are a common group considered for trials, since standard RAI treatment no longer works once cancer cells stop absorbing iodine well. People with medullary thyroid cancer, especially if it has spread or is no longer controlled by surgery, may also be candidates, particularly for trials studying RET targeted drugs. Genetic testing for RET mutations is recommended for everyone diagnosed with medullary thyroid cancer, both to guide family screening and because it can help match you to a targeted therapy trial.
Anaplastic thyroid cancer is where clinical trials often play the biggest role, because so few standard options exist and the disease moves quickly. Trials studying targeted therapy combinations, particularly for tumors with a BRAF V600E mutation, have produced some of the most promising results seen in this disease in years. If you or a loved one has been diagnosed with anaplastic thyroid cancer, asking about a clinical trial early, sometimes within days of diagnosis, is a reasonable and often recommended step, not something to delay.
There are real benefits to joining a trial. You may gain access to a promising new treatment before it is widely available, and you will typically be watched very closely by a research team, which adds an extra layer of monitoring to your care. You also contribute directly to research that can help future patients with your same diagnosis.
There are honest tradeoffs too. A treatment being studied may not work better than, or may not work as well as, standard treatment. It may cause side effects that are hard to predict since it is still being studied. Trials usually require more frequent visits, more tests, and sometimes travel to a specific research site, which can be tiring and disruptive to daily life. None of these tradeoffs mean a trial is a bad choice, but they are worth thinking through honestly with your family and your care team.
One of the most important things to understand is that a clinical trial does not have to be a last resort. Many patients and families only think about trials once other options have run out, but bringing it up early, even at diagnosis, gives you and your care team more time to research options, check eligibility, and plan around timing. This is especially true for anaplastic thyroid cancer, where speed matters, but it is worth considering for any thyroid cancer diagnosis where you want to understand the full range of choices. You can read more about how thyroid cancer is staged and how that staging can shape these conversations.
How Do You Find a Clinical Trial for Thyroid Cancer?
The most direct first step is to ask your oncologist or endocrinologist whether a clinical trial might be appropriate for your situation. Your own care team knows your diagnosis, your prior treatments, and your overall health, and they may already know about trials open at their institution or nearby that fit your case. Do not hesitate to raise the topic yourself if it has not come up. Many patients worry that asking about a trial will upset their doctor or suggest they have given up on standard care, but bringing it up is a normal, welcomed part of a thorough discussion of your options.
HealthTree's clinical trial finder lets you search specifically for thyroid cancer trials by cancer subtype, location, and other factors, and is built to be usable directly by patients and caregivers, not just doctors. In order to see a personalized list of clinical trail you need to connect your medical records to HealthTree.
Connect your medical records to HealthTree
Academic thyroid cancer centers, meaning hospitals affiliated with universities or NCI Designated Cancer Centers, often run more thyroid cancer trials than smaller community practices, simply because they have larger research programs and see more people with rarer subtypes like medullary and anaplastic thyroid cancer. If your current care is at a smaller clinic, ask whether a referral or a second opinion at a larger academic center makes sense, even if you plan to continue most of your care closer to home.
Biomarker testing, meaning lab testing of your tumor for specific genetic changes, is central to matching people with thyroid cancer to the right trial. BRAF V600E testing matters most for papillary thyroid cancer and for anaplastic thyroid cancer, since it identifies people who may benefit from BRAF targeted trials. RET testing matters most for medullary thyroid cancer, and also identifies a subset of papillary thyroid cancer driven by RET changes. Ask your doctor whether your tumor has been tested for these changes, since the results can open up trial options that would not otherwise be visible to you. You can learn more about how thyroid cancer is diagnosed, including this kind of tumor testing, in our companion guide.
Finally, do not underestimate patient advocacy and support organizations as a source of leads. Groups focused specifically on thyroid cancer, along with your own support network, sometimes know about newly opened trials before they are widely publicized, and can help you understand what a listing on a registry actually means in plain language.
Research team members
Designing and running a clinical trial requires the skills of many experts. Different sites of the same trial may set up their teams differently. Typical team members and their duties include:
Title | Role | Responsibility |
|---|---|---|
Principal investigator | Supervises all aspects of a clinical trial |
|
Research nurse | Helps take care of the patients during a clinical trial |
|
Data manager | Manages the collection of data throughout the clinical trial |
|
Staff physician or nurse | Helps take care of the patients during a clinical trial |
|
Questions to Ask Before Joining a Clinical Trial
Once you have found a trial that looks like a possible fit, bring a list of questions to your appointment with the research team. It is easy to forget questions in the moment, so writing them down ahead of time and bringing someone with you to take notes can help.
Purpose: What is this trial trying to find out, and why do the researchers think this treatment might help my specific type of thyroid cancer?
Eligibility: Why do I qualify for this trial, and what would disqualify me if my situation changes?
What is required of me: How many visits will I need to make, how long will the trial last, and will I need to travel or stay near the trial site?
Risks: What are the known and possible side effects of the treatment being studied, and how do they compare with the side effects of my standard treatment options?
Benefits: What are the realistic potential benefits, and how likely am I to experience them?
Costs: Which costs will the trial sponsor or my insurance cover, and which costs would I be responsible for, including travel, lodging, or lost work time?
Alternatives: What would happen to my cancer, and what other treatment choices would I have if I decided not to join this trial?
Leaving the trial: If the treatment is not working for me, or if I simply want to stop, can I leave the trial at any time, and what would my treatment options be afterward?
Asking these questions is not a sign of distrust. Research teams expect and welcome them, and a good team will take the time to answer clearly before asking you to sign a consent form. You always have the right to say no, to ask for more time to decide, or to leave a trial later if it is not right for you. For a broader list of questions to bring to any thyroid cancer appointment, see our guide on questions to ask about thyroid cancer.
You can email, call, or chat with HealthTree's Patient Experience team for help finding or enrolling in a clinical trial.